Homepage Top Section2

The deal grants Genentech exclusive global rights to develop and commercialise the selected RNAi programme. According to the contract, SanegeneBio will manage early development activities while Genentech will

The CHMP recommends the use of niraparib and abiraterone acetate with prednisone or prednisolone (AAP), along with androgen deprivation therapy (ADT), specifically for patients with metastatic hormone-sensitive prostate

As part of this agreement, Boehringer Ingelheim will utilise IQVIA’s data-as-a-service (DaaS+) technology to advance its global commercial data transformation, aiming to streamline data management and analytics across

The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova

Otsuka’s NDA covers the use of centanafadine as a treatment for ADHD in adolescents, adults, and children. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The

Agreed in December 2025, the transaction is valued at up to $820m and brings the late-stage monoclonal antibody brelovitug, a candidate for chronic hepatitis delta virus (HDV), into

For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03. The diluted earnings per share (EPS) for Q4 2025

The new solution is intended for pharmaceutical and medical device manufacturers, enabling them to train operators, guide execution, and verify critical tasks using advanced AI-technologies. Pharmaceutical manufacturers frequently

The acquisition gives AstraZeneca full global control over the development, manufacturing, and commercialisation of the therapy. AbelZeta will receive up to $630m from AstraZeneca, including upfront payments and